Patents by Inventor Kevin Pong
Kevin Pong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240161035Abstract: A medical scan viewing system is configured to: generate inference data via at least one inference function, based the at least one medical scan and further based on receiver operating characteristic (ROC) parameters that include at least one ROC set point; present for display, via an interactive user interface, medical image data corresponding to the at least one medical scan, the inference data and a ROC adjustment tool; generate, in response to user interaction with the ROC adjustment tool, at least one adjusted ROC set point; generate updated inference data via the at least one inference function, based the at least one medical scan and further based on the at least one adjusted ROC set point; and present for display, via the interactive user interface, the medical image data corresponding to the at least one medical scan and the updated inference data.Type: ApplicationFiled: December 22, 2022Publication date: May 16, 2024Applicant: Enlitic, Inc.Inventors: Kevin Lyman, Anthony Upton, Jordan Francis, Vicky Li, Mark Freudenberg, Alexander Pong, Alexander Freska, Zachary Holt
-
Publication number: 20240112945Abstract: In one embodiment, a susceptor for thermal processing is provided. The susceptor includes an outer rim surrounding and coupled to an inner dish, the outer rim having an inner edge and an outer edge. The susceptor further includes one or more structures for reducing a contacting surface area between a substrate and the susceptor when the substrate is supported by the susceptor. At least one of the one or more structures is coupled to the inner dish proximate the inner edge of the outer rim.Type: ApplicationFiled: December 14, 2023Publication date: April 4, 2024Inventors: Anhthu NGO, Zuoming ZHU, Balasubramanian RAMACHANDRAN, Paul BRILLHART, Edric TONG, Anzhong CHANG, Kin Pong LO, Kartik SHAH, Schubert S. CHU, Zhepeng CONG, James Francis MACK, Nyi O. MYO, Kevin Joseph BAUTISTA, Xuebin LI, Yi-Chiau HUANG, Zhiyuan YE
-
Patent number: 8283373Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.Type: GrantFiled: June 19, 2009Date of Patent: October 9, 2012Assignee: Pfizer Inc.Inventors: John C. McKew, Katherine L. Lee, Lihren Chen, Richard Vargas, James D. Clark, Cara Williams, Valerie Clerin, Suzana Marusic, Kevin Pong
-
Patent number: 8030325Abstract: A polyketide synthase complex composed of polyketide synthase with 15 total modules, a non-ribosomal peptide synthetase with 1 module, and a cytochrome P450 hydroxylase is described. Also provided are novel Streptomyces species and methods of modified Streptomyces species. Further described are novel compounds, 36-ketomeridamycin, C9-deoxomeridamycin, and C9-deoxoprolylmeridamcyin and uses thereof.Type: GrantFiled: July 25, 2008Date of Patent: October 4, 2011Assignee: Wyeth LLCInventors: Min He, John Hucul, Bradley Arnold Haltli, Melissa M. Wagenaar, Edmund Idris Graziani, Mia Summers, Kerry Kulowski, Kevin Pong, Xidong Feng
-
Publication number: 20110144176Abstract: This invention relates, in part, to macrolide compounds, actinomycete strains for producing them, and pharmaceutical compositions containing them.Type: ApplicationFiled: December 15, 2010Publication date: June 16, 2011Applicant: Wyeth LLCInventors: Mia Haruna Yoshino SUMMERS, Edmund Idris Graziani, Margaret M. Leighton, Kevin Pong, Roger Alan Kele, David P. Labeda
-
Patent number: 7906548Abstract: This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.Type: GrantFiled: August 11, 2009Date of Patent: March 15, 2011Assignee: Wyeth LLCInventors: John C. McKew, Steve Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark L. Behnke, Baihua Hu, James D. Clark, Wei Li, Valerie Clerin, Suzana Marusic, Kevin Pong
-
Patent number: 7795252Abstract: The present invention provides for methods of treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders using compounds of the following structure: The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.Type: GrantFiled: June 9, 2009Date of Patent: September 14, 2010Assignee: Pfizer Inc.Inventors: Edmund Idris Graziani, Kevin Pong, Jerauld S. Skotnicki
-
Publication number: 20100196355Abstract: Immunophilin ligands and their uses as modulators of calcium channel activity are disclosed. Screening, therapeutic and prophylactic methods for conditions associated with calcium channel dysfunction, e.g., neurodegenerative and cardiovascular disorders, are also disclosed.Type: ApplicationFiled: January 29, 2007Publication date: August 5, 2010Applicant: WyethInventors: Edmund Idris Graziani, Benfang Helen Ruan, Kevin Pong, Mark Robert Bowlby
-
Patent number: 7745457Abstract: A compound of the structure is described. This compound and its use for preparing medicines useful in the treatment of neurodegenerative disorders is described.Type: GrantFiled: March 5, 2007Date of Patent: June 29, 2010Assignee: Wyeth LLCInventors: Edmund Idris Graziani, Kevin Pong
-
Publication number: 20100035957Abstract: This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.Type: ApplicationFiled: August 11, 2009Publication date: February 11, 2010Inventors: John C. McKew, Steve Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark L. Behnke, Baihua Hu, James D. Clark, Wei Li, Valerie Clerin, Suzana Marusic, Kevin Pong
-
Publication number: 20100029645Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.Type: ApplicationFiled: June 19, 2009Publication date: February 4, 2010Inventors: John C. McKew, Katherine L. Lee, Lihren Chen, Richard Vargas, James D. Clark, Cara Williams, Valerie Clerin, Suzana Marusic, Kevin Pong
-
Publication number: 20100022536Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.Type: ApplicationFiled: June 19, 2009Publication date: January 28, 2010Inventors: John C. McKew, Katherine L. Lee, Lihren Chen, Richard Vargas, James D. Clark, Cara Williams, Valerie Clerin, Suzana Marusic, Kevin Pong
-
Patent number: 7605156Abstract: This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.Type: GrantFiled: May 27, 2005Date of Patent: October 20, 2009Assignee: WyethInventors: John C. McKew, Steve Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark L. Behnke, Baihua Hu, James D. Clark, Wei Li, Valerie Clerin, Suzana Marusic, Kevin Pong
-
Publication number: 20090239855Abstract: The present invention provides for methods of treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders using compounds of the following structure: The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.Type: ApplicationFiled: June 9, 2009Publication date: September 24, 2009Applicant: WyethInventors: Edmund Idris Graziani, Kevin Pong, Jerauld Skotnicki
-
Publication number: 20090209527Abstract: The present invention provides methods for treatment of neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders, comprising administering a compound as described herein to a subject in need thereof, and a pharmaceutically acceptable carrier, within a therapeutic window that is from about 4 hours to 24 hours, or longer, for example at least 4, 6, 9, 12, 15, 18, 21 or 24 hours, or longer, after the onset of the neurological, proliferative, or inflammatory disorder or a symptom thereof.Type: ApplicationFiled: February 19, 2009Publication date: August 20, 2009Applicant: WyethInventors: Kevin Pong, Margaret Maria Zaleska
-
Publication number: 20090203682Abstract: Method of treatment of neurological disorders or complications due to stroke or head injury through the administration of a pharmaceutical composition including a pharmaceutically acceptable excipient or carrier and a compound of formula I are provided:Type: ApplicationFiled: November 24, 2008Publication date: August 13, 2009Applicant: WyethInventors: Edmund Idris Graziani, Kevin Pong, Jerauld Skotnicki
-
Patent number: 7560457Abstract: The present invention provides compounds of the following structure, wherein R1, R2, R4, R4?, R6, R7, and R15 are defined above: These compounds are useful in treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders. The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.Type: GrantFiled: January 26, 2007Date of Patent: July 14, 2009Assignee: WyethInventors: Edmund Idris Graziani, Kevin Pong, Jerauld Skotnicki
-
Patent number: 7557135Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.Type: GrantFiled: May 26, 2006Date of Patent: July 7, 2009Assignee: WyethInventors: John C. McKew, Katherine L. Lee, Lihren Chen, Richard Vargas, James D. Clark, Cara Williams, Valerie Clerin, Suzana Marusic, Kevin Pong
-
Publication number: 20090105294Abstract: A polyketide synthase complex composed of polyketide synthase with 15 total modules, a non-ribosomal peptide synthetase with 1 module, and a cytochrome P450 hydroxylase is described. Also provided are novel Streptomyces species and methods of modified Streptomyces species. Further described are novel compounds, 36-ketomeridamycin, C9-deoxomeridamycin, and C9-deoxoprolylmeridamcyin and uses thereof.Type: ApplicationFiled: July 25, 2008Publication date: April 23, 2009Applicant: WyethInventors: Min He, John Hucul, Bradley Arnold Haltli, Melissa M. Wagenaar, Edmund Idris Graziani, Mia Summers, Kerry Kulowski, Kevin Pong, Xidong Feng
-
Publication number: 20090088448Abstract: Provided is a method of treating neurodegenerative disorders comprising administering to a subject in need thereof a compound of formula I:Type: ApplicationFiled: December 5, 2008Publication date: April 2, 2009Applicant: WyethInventors: Edmund Idris Graziani, Kevin Pong, Jerauld Skotnicki